Search
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesCinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalThe approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted … Panobinostat is marketed by Novartis under the brand name Farydak.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsChlormerodrin Hg-197
go.drugbank.com/drugs/DB09406ApprovedChlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.
Synonyms: Chlormerodrin Hg 197, Chlormerodrin Hg-197Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
Nephrotic syndrome with lesion of minimal change glomerulonephritis
go.drugbank.com/conditions/DBCOND0089324Synonyms: Nephrotic syndrome due to minimal change disease, Nephrotic syndrome due to minimal change disease (disorder)Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalFebrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy … [L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34.
rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Verubecestat
go.drugbank.com/drugs/DB12285InvestigationalIn the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … 57, 79 and 84 percent, respectively.